AP NEWS

Global House Dust Mite Allergy Market Analysis & Outlook 2018-2027 - ResearchAndMarkets.com

December 7, 2018

DUBLIN--(BUSINESS WIRE)--Dec 7, 2018--The “House Dust Mite Allergy - Market Insights, Epidemiology and Market Forecast” drug pipelines has been added to ResearchAndMarkets.com’s offering.

In 2016, global market size of House Dust Mite Allergy was USD 258 million and is expected to grow during the forecast period of 2018-2027.

Odactra by Merck Sharp & Dohme Corp. and Actair by Shionogi & Co. are currently approved therapies for House Dust Mite Allergies.

The disease epidemiology covered in the report is segmented into two parts: Total Prevalent Population of Respiratory Allergy and Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan].

According to the report, the prevalent cases of House Dust Mite Induced Respiratory Allergy was 50,703,100 in 2016 in 7MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of House Dust Mite Allergy with 69,310,852 prevalent cases in 2016.

Report Coverage

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of House Dust Mite Allergy from 2016 to 2027 segmented by the US, EU-5 countries and Japan.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Companies Featured

Merck Sharp & Dohme Corp. Shionogi & Co.

Key Topics Covered

1. Key Insights

2. House Dust Mite Allergy Market Overview at a Glance

3. House Dust Mite Allergy: Disease Background and Overview

4. Epidemiology and Patient Population

5. 7MM Total Prevalence of HDM Induced Respiratory Allergy

6. Country Wise-Epidemiology of House Dust Mite Allergy

7. Unmet Needs

8. Marketed Drug Analysis

9. House Dust Mite Allergy: 7 Major Market Analysis

10. The United States Market Outlook

11. EU-5 Countries: Market Outlook

12. Market Drivers

13. Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/97gp3s/global_house_dust?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181207005353/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/07/2018 11:08 AM/DISC: 12/07/2018 11:07 AM

http://www.businesswire.com/news/home/20181207005353/en

AP RADIO
Update hourly